Imbruvica, which is sold by Pharmacyclics (NASDAQ: PCYC) and Johnson & Johnson ( JNJ -1.82% ), beat GlaxoSmithKline 's Arzerra in a head-to-head trial comparing the two drugs in patients with chronic lymphocytic leukemia. Imbruvica produced a 78% reduction in progression-free survival and an 85% response rate, compared with just 23% for Arzerra. Pharmacyclics and Johnson & Johnson look poised to take market share from Arzerra. We also saw a battle between Clovis ( CLVS ) and AstraZeneca ( AZN 0.46% ), although it wasn't of the head-to-head variety.